<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980730</url>
  </required_header>
  <id_info>
    <org_study_id>TTP488-305</org_study_id>
    <nct_id>NCT03980730</nct_id>
  </id_info>
  <brief_title>Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance</brief_title>
  <acronym>Elevage</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled, Multicenter Studies to Evaluate the Safety and Efficacy of Azeliragon as a Treatment for Subjects With Mild Alzheimer's Disease and Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>vTv Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>vTv Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy and safety of azeliragon in patients with mild
      Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon
      or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21
      months (in Part 2).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 : Change from Baseline in the Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-cog14) at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>The ADAS-cog14 scoring range is from 0 to 90, with higher scores indicating greater cognitive impairment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in the ADAS-cog14 at Month 18</measure>
    <time_frame>18 months</time_frame>
    <description>The ADAS-cog14 scoring range is from 0 to 90, with higher scores indicating greater cognitive impairment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in Clinical Dementia Rating Scale-Sum of Boxes (CDR-sb) at Month 18</measure>
    <time_frame>18 months</time_frame>
    <description>Sum of box scores range from 0 to 18 with higher scores indicating greater cognitive impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change from Baseline in the Clinical Dementia Rating Scale-Sum of Boxes (CDR-sb) at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>Sum of box scores range from 0 to 18 with higher scores indicating greater cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change from Baseline in the Functional Activities Questionnaire (FAQ) at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>The total FAQ score ranges from 0 to 30, with higher scores indicating greater functional loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change from Baseline in the Amsterdam-Instrumental Activities of Daily Living (Amsterdam-IADL) at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>The A-IADL total score is calculated using an item response theory method of scoring and lower scores indicate greater functional impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change from Baseline in estimated glomerular filtration rate (eGFR) at Month 6</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Responder status at Months 6, 12, and 18 based on the ADAS-cog14</measure>
    <time_frame>6, 12, 18 months</time_frame>
    <description>The ADAS-cog14 scoring range is from 0 to 90, with higher scores indicating greater cognitive impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from Baseline in FAQ score at Month 18</measure>
    <time_frame>18 months</time_frame>
    <description>The total FAQ score ranges from 0 to 30, with higher scores indicating greater functional loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from Baseline in Amsterdam-IADL score at Month 18</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from Baseline in MMSE score at Month 18</measure>
    <time_frame>18 months</time_frame>
    <description>MMSE scores range from 0-30 with lower scores indicating greater cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from Baseline in eGFR at Month 18</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from Baseline in whole brain volume at Month 18</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportions of subjects with treatment-emergent adverse events</measure>
    <time_frame>3,6 months (Part 1) ; 3,6,9,12,15,18 months (Part 2)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportions of subjects with treatment-emergent abnormal clinical laboratory values</measure>
    <time_frame>3,6 months (Part 1) ; 3,6,9,12,15,18 months (Part 2)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportions of subjects with abnormal values or changes in vital signs measures of potential clinical concern</measure>
    <time_frame>3,6 months (Part 1) ; 3,6,9,12,15,18 months (Part 2)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportions of subjects with treatment-emergent 12-lead ECG results of potential clinical concern</measure>
    <time_frame>3,6 months (Part 1) ; 3,6,9,12,15,18 months (Part 2)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Part 2: Change from Baseline at Month 18 for Neuropsychiatric Inventory</measure>
    <time_frame>18 months</time_frame>
    <description>Scores range from 0-144 with higher scores indicating a greater presence of neuropsychiatric symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 2: Change from Baseline at Month 18 Dementia Quality of Life (DEMQOL-proxy)</measure>
    <time_frame>18 months</time_frame>
    <description>Higher scores indicate better health related quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Part 2: Change from Baseline in plasma concentrations of AÎ² species at Month 18</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Part 2: Change from Baseline in brain MRI (hippocampal, ventricular) volumetric measures at Month 18</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Azeliragon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azeliragon 5mg capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsule administered orally, once daily for 6 months (Part 1) or 18 months (Part 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azeliragon</intervention_name>
    <description>Azeliragon 5 mg capsule administered orally, once daily</description>
    <arm_group_label>Azeliragon</arm_group_label>
    <other_name>TTP488</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsule administered orally, once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression
             of disease

          -  Mini Mental State Examination (MMSE) score of 21-26, inclusive

          -  Clinical Dementia Rating global score of 0.5 or 1

          -  Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog14) of 10 or more

          -  Brain magnetic resonance imaging (MRI) consistent with the diagnosis of probable AD

          -  Concurrent use of cholinesterase inhibitor or memantine with stable dose for at least
             2 months prior to screening

          -  Hemoglobin A1c (HbA1c) 6.5% - 9.5%, inclusive

          -  Caregiver willing to participate and be able to attend clinic visits with patient

          -  Ability to ingest oral medications

        Exclusion Criteria:

          -  Significant neurological or psychiatric disease other than Alzheimer's disease

          -  Previous clinical trial participation within 90 days of screening

          -  Previous exposure to putative disease modifying therapy for Alzheimer's disease within
             1 year of screening

          -  History of cancer within the last 5 years except adequately treated cervical carcinoma
             in-situ, cutaneous basal cell or squamous cell cancer, or non-progressive prostate
             cancer not requiring current treatment

          -  Women of childbearing potential

          -  Uncontrolled blood pressure and/or blood pressure above 140/90

          -  Participants receiving medications that may negatively impact cognitive function

          -  History of diabetic ketoacidosis within the past year

          -  History of chronic pancreatitis

          -  Stage 4 kidney disease

          -  Use of insulin therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ann Gooch, PhD</last_name>
    <phone>336-888-0435</phone>
    <email>clinicaltrials@vtvtherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tucson Neuroscience Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charter Research</name>
      <address>
        <city>Lady Lake</city>
        <state>Florida</state>
        <zip>32159</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Research and Treatment Center</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinCloud</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emerald Coast Center for Neurological Disorders</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Roskamp Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34997</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory Alzheimer's Clinical Research Unit</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NeuroStudies.net LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IU Health Partners, Adult Neurology Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memory Center / Hattiesburg Clinic</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Millennium Psychiatric Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cognitive and Research Center of New Jersey</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albuquerque Neuroscience Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clarity Clinical Research</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurological Associates of Long Island</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ANI Neurology dba Alzheimer's Memory Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ANI Neurology, PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Summit Research Network</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Center for Cognitive Health</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okanagan Clinical Trials Ltd.</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>True North Clinical Research Inc.</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3S 1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>True North Clinical Research Inc.</name>
      <address>
        <city>Kentville</city>
        <state>Nova Scotia</state>
        <zip>B4N 4K9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Recherches Neuro-Hippocampe</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Z IG3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Recherches Neuro-Hippocampe Inc.</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8T 8J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Q&amp;T Research Sherbrooke Inc</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Receptor for Advanced Glycation Endproducts (RAGE)</keyword>
  <keyword>ADAS-cog</keyword>
  <keyword>CDR-sb</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

